Actively Recruiting
Evaluation of Intermittent Triple Therapies in Real Life
Led by University Hospital, Strasbourg, France · Updated on 2024-08-29
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al. Currently this strategy is proposed by some teams in France, but is not recommended internationally. The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.
CONDITIONS
Official Title
Evaluation of Intermittent Triple Therapies in Real Life
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult subject (18 years old or older)
- Living with HIV and monitored at the Trait d'Union/Infectious Diseases department in Strasbourg
- Have received intermittent triple therapy between 01/01/2017 and 31/01/2024
You will not qualify if you...
- Subject or their legal representative has opposed reuse of their data for scientific research purposes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service Le Trait d'Union - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
A
Axel URSENBACH, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here